Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial

作者：Tiseo Marcello^*; Boni Luca; Ambrosio Francesca; Camerini Andrea; Vitale Maria Giuseppa; Baldini Editta; Cinieri Saverio; Zanelli Francesca; Defraia Efisio; Passalacqua Rodolfo; Crino Lucio; Dazzi Claudio; Tibaldi Carmelo; Turolla Gianni M; D'Alessandro Vito; Zilembo Nicoletta; Riccardi Ferdinando; Ardizzoni Andrea

来源：Clinical Lung Cancer, 2015, 16(1): 67-70.

DOI：10.1016/j.cllc.2014.09.001

• Bevacizumab
• Extended disease
• SCLC
• Vascular endothelial growth factor

Background: Neoangiogenesis is particularly abundant in small-cell lung cancer (SCLC) and is associated with poor prognosis. As a result of the promising nature of phase II studies, a randomized phase III trial was designed to assess the efficacy of adding bevacizumab to first-line chemotherapy with cisplatin-etoposide for treatment of extensive disease SCLC. We present the treatment rationale and study design of GOIRC trial (FARM6PMFJM study), a multicenter randomized phase III study, supported by AIFA (Agenzia Italiana del Farmaco). Patients and Methods: Patients are randomized to receive either cisplatin 25mg/m(2) and etoposide 100mg/m(2) intravenously on days 1 to 3 (control arm) or the same chemotherapy combined with bevacizumab 7.5 mg/kg intravenously on day 1 (experimental arm). Treatment is repeated every 3 weeks and for a maximum of 6 courses. Patients randomized to the experimental arm in the absence of disease progression after 6 cycles continue bevacizumab alone until progression or for amaximumof 18 courses. Tumor assessment is done every 3 cycles. Major eligibility criteria are: age >= 18 years; histologically or cytologically documented extensive disease SCLC; Eastern Cooperative Oncology Group performance status >= 2; adequate hematological, hepatic and renal functions; no history of grade 2 or higher hemoptysis; and no evidence of tumor cavitation. The primary end point of this study is overall survival. Secondary end points include response rate, time to progression, and toxicity. Conclusion: An interim futility analysis was performed by an Independent Data Monitoring Committee in September 2013 and the trial obtained approval to continue. As of July 31, 2014, 171 patients of 206 planned have been randomized.

• 出版日期2015-1
• 单位Perugia